SEPT5 Antibody

Code CSB-PA030106
Size US$119
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
SEPT5
Alternative Names
5 Sep antibody; CDCrel 1 antibody; CDCREL antibody; CDCrel-1 antibody; CDCREL1 antibody; Cell division control related protein 1 antibody; Cell division control-related protein 1 antibody; H5 antibody; HCDCREL 1 antibody; OTTHUMP00000197271 antibody; OTTHUMP00000197272 antibody; OTTHUMP00000197273 antibody; OTTHUMP00000197274 antibody; OTTHUMP00000197275 antibody; OTTHUMP00000197276 antibody; OTTHUMP00000197396 antibody; OTTHUMP00000197410 antibody; Peanut like 1 antibody; Peanut like 1 homolog antibody; Peanut like protein 1 antibody; Peanut-like protein 1 antibody; Platelet glycoprotein Ib beta chain antibody; PNUTL1 antibody; SEPT5 antibody; SEPT5_HUMAN antibody; Septin 5 antibody; Septin-5 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Synthesized peptide derived from the Internal region of Human Septin 5.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
ELISA 1:10000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Filament-forming cytoskeletal GTPase. May play a role in cytokinesis (Potential). May play a role in platelet secretion.
Gene References into Functions
  1. CDCrel-1 overexpression exerts dopamine-dependent neurotoxicity and may contribute to the development of autosomal-recessive juvenile parkinsonism PMID: 14530399
  2. We studied the assembly of three human septins, SEPT4, SEPT5 and SEPT8, with each other (heterotypic) and with themselves (homotypic) using a yeast two-hybrid system. PMID: 15214843
  3. the high expression levels of PNUTL1 in human pancreatic endocrine cells that suggests a similar role of this protein in islet cells to that demonstrated in neuronal tissues, and warrants further functional studies of this protein. PMID: 16179808
  4. Our finding suggests a role for members of the septin family in the development of proliferative retinal membranes. PMID: 17625225
  5. HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity PMID: 18398426

Show More

Hide All

Subcellular Location
Cytoplasm. Cytoplasm, cytoskeleton. Note=In platelets, found in areas surrounding alpha-granules.
Protein Families
TRAFAC class TrmE-Era-EngA-EngB-Septin-like GTPase superfamily, Septin GTPase family
Tissue Specificity
Expressed at high levels in the CNS, as well as in heart and platelets (at protein level).
Database Links

HGNC: 9164

OMIM: 602724

KEGG: hsa:5413

STRING: 9606.ENSP00000391311

UniGene: Hs.728762

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*